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Treatment of patients with chronic myeloid leukaemia (CML) has become increasingly diffi-
cult in recent years due to the variety of treatment options available and challenge deciding
on the most appropriate treatment strategy for an individual patient. To facilitate the treatment
strategy decision, disease assessment should involve molecular response to initial treatment
for an individual patient. Patients predicted not to achieve major molecular response (MMR)
at 24 months to frontline imatinib may be better treated with alternative frontline therapies,
such as nilotinib or dasatinib. The aims of this study were to i) understand the clinical predic-
tion ‘rules’ for predicting MMR at 24 months for CML patients treated with imatinib using clini-
cal, molecular, and cell count observations (predictive factors collected at diagnosis and
categorised based on available knowledge) and ii) develop a predictive model for CML treat-
ment management. This predictive model was developed, based on CML patients undergo-
ing imatinib therapy enrolled in the TIDEL II clinical trial with an experimentally identified
achieving MMR group and non-achieving MMR group, by addressing the challenge as a
machine learning problem. The recommended model was validated externally using an inde-
pendent data set from King Faisal Specialist Hospital and Research Centre, Saudi Arabia.
Principle Findings
The common prognostic scores yielded similar sensitivity performance in testing and valida-
tion datasets and are therefore good predictors of the positive group. The G-mean and F-
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score values in our models outperformed the common prognostic scores in testing and vali-
dation datasets and are therefore good predictors for both the positive and negative groups.
Furthermore, a high PPV above 65% indicated that our models are appropriate for making
decisions at diagnosis and pre-therapy. Study limitations include that prior knowledge may
change based on varying expert opinions; hence, representing the category boundaries of
each predictive factor could dramatically change performance of the models.
Introduction
Chronic myeloid leukaemia (CML) is a malignant blood cancer that results in overproduction
of myeloid cells in bone marrow, leading to significant increase in the number of immature
white cells circulating in an affected person’s blood. The causative chromosomal translocation,
known as the Philadelphia chromosome (Ph), in CML gives rise to the BCR-ABL1 gene,
which encodes for the constitutively active tyrosine kinase Bcr-Abl [1]. The need for personal-
ised medicine in CML refers to multiple active tyrosine kinase inhibitor (TKI) therapies avail-
able for CML, multiple strategies utilised for frontline CML therapy, and heterogeneity in
responses. The first generation TKI, imatinib (IM) (Glivec1), is a standard strategy used over
the past decade [2], but some patients exhibit a poor response to this therapy. These patients
may benefit from a second generation TKI, such as nilotinib (NIL) (Tasigna1) or dasatinib
(DAS) (Sprycel1). Each of these TKIs are currently approved for use as frontline treatment in
CML. Therefore, frontline CML therapy occurs via one of two major strategies: i) frontline IM
or ii) frontline second generation TKIs, such as NIL or DAS[3]. Hematologic, cytogenetic, and
molecular strategies for monitoring patient responses to therapies are used by European Leu-
kaemiaNet [4]. To monitor molecular response, real-time quantitative polymerase chain reac-
tion (RQ-PCR) is used to quantify the level of BCR-ABL1 mRNA transcripts in peripheral
blood of patients. According to the international scale, the two main molecular responses are
major molecular response (MMR; BCR-ABL1 transcript 0.10%) and complete molecular
response (CMR; BCR-ABL1 transcripts not detectable). Molecular monitoring is considered a
standard guide to clinical management in CML [5, 6]. Prediction of the long-term molecular
response to frontline IM in CML can support clinicians to select optimum treatment protocols
for CML patients. Patients predicted not to achieve MMR at 24 months may be better treated
with alternative frontline therapies, such as NIL or DAS.
The application of machine learning in medicine reduces the gap between clinical research
and clinical practice. This type of model may be useful for clinicians in decision-making by
warning of specific problems or providing treatment recommendations [7]. There is a need to
adapt machine learning technology to deal with the high complexity of the medical domain.
Coping with the complexity of cancer patient management, we used machine learning to drive
hidden information and transfer evidence into practice. Incorporating prior domain knowl-
edge and raw data into machine learning algorithms makes the best use of information from
various data sources. Using machine learning algorithms as a ‘white box’ model results in eas-
ier and more interpretable mathematical models that lead to simple and clear decisions. The
decision is generated on the basis of expert experience. Thus, it is important to incorporate
prior knowledge to classify medical data and identify the relation between different predictive
factors.
CML treatment predictive models emulate the decision-making ability of a human expert
and provide recommendations for clinicians based on early prediction of patient molecular
responses to specific treatment. Thus, predictive models predicting MMR to TKI therapy from
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a CML patient’s clinical, molecular, and blood count factors at diagnosis have the potential to
support clinicians manage CML treatment more effectively. This study aimed to i) understand
whether there exist rules for predicting MMR at 24 months for CML patients treated with IM
from the clinical, molecular, and cell count observations collected at diagnosis and categorised
based on the available knowledge and ii) build a predictive model to predict MMR for IM in
CML patients with better prediction results than those obtained with predictive assays and pre-
vious scores. CML patients predicted not to achieve MMR at 24 months may be better treated
with alternative frontline therapies, including second generation TKIs, such as NIL and DAS.
Related work
A predictive factor is a patient characteristic used to predict treatment response [8]. Predictive
factors related to MMR response include common molecular assays. Other factors depend on
peripheral blood counts as well as molecular-based and clinical observations of the individual
patient. In order to select the most effective TKI therapy at the time of diagnosis, various pre-
dictive factors in CML have been investigated to distinguish patients at increased risk of failure
with IM, the first generation TKI [9–12]. Table 1 shows the current predictive assays and score
systems, factors included in the score systems and methods used, target prediction, and pub-
lished results.
Two common predictive assays, namely OCT-1 activity (OA)[13, 18, 19] and IC50IM[14],
have been studied to distinguish CML patients likely to achieve a good molecular response to
IM. CML patients with the b3a2 BCR-ABL1 transcript type, compared to those with the b2a2
transcript, demonstrate greater survival rates, while CML patients with the p190 transcript
type are classified as high risk [20, 21].
Three common prognostic scoring systems have been developed to identify CML patient
risk groups: the Sokal [15], Hasford [16], and European Treatment and Outcome Study
(EUTOS)[17] scores. The Sokal score is derived using age, spleen size, platelet count, and
peripheral blood blasts; the Hasford score also uses peripheral blood eosinophil and basophil
percentage; and the EUTOS score is based on percentage of basophils and spleen size. These
three scores ascertain the level of risk for CML patients by running multivariable regression
analysis. However, these scoring systems were developed in the era when chemotherapy was
the only therapy available. The EUTOS score was developed to predict cytogenetic response to
IM therapy and failed to predict MMR[22]. Although prognostic scores are currently used to
Table 1. The current predictive assays and score systems, the factors included in score systems and the methods used; the target prediction and
final results.
Previous methods
Study Factors Method Target prediction Data and Results
White et al. [13] OA (ng/200,000 cells) Kaplan Meier
Analysis
MMR by 60 months to
IM
TIDEL I clinical trial (n = 56), High OA: 89%,
and low OA: 55%
White et al. [14] IC50IM (μM) Kaplan Meier
Analysis
MMR by 12 months to
IM
TIDEL I clinical trial (n = 116), Low IC50IM:
65%, and High IC50IM: 39%
Sokal Score,
Sokal et al. [15]






Six European and American sources
(n = 813), Low 39%, intermediate 38%, and
high 23%
Hasford Score,
Hasford et al. [16]
Age, spleen size (cm), blasts (%),






14 studies (n = 981), Low 40.6%,
intermediate 44.7%, and high 14.6%
EUTOS Score,
Hasford et al. [17]
Basophils (%) and spleen Size (cm) Multivariate
analysis of
response
CCgR at 18 months to
IM
Five national study group (n = 2060), Low
79%, and high 21%
doi:10.1371/journal.pone.0168947.t001
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personalise the care of CML patients by predicting response to therapy, they were developed
either for identifying risk groups or for predicting cytogenetic response to therapy, but not for
molecular response.
A recent study investigated the possible association between molecular response and a
number of factors, such as Sokal score, age, sex, and IM dose [23], and found that female sex is
a strong predictor. A recent review of biomarkers that determine prognosis in CML also pre-
sented a list of prognostic indicators at diagnosis, such as the three scoring systems, BCR-ABL1
transcript type, and OA[24]. However, to our knowledge, relations between predictive factors
to predict molecular response have not previously been considered.
Materials and Methods
Dataset
Patients from the Therapeutic Intensification in De Novo Leukaemia (TIDEL II) [25] clinical
trial were eligible for the study. Two sequential cohorts of 105 CML patients (total of 210)
received IM 600 mg as the initial therapy. All patients were in chronic phase and monitored for
time-dependent molecular response targets. For the long-term prediction, we considered achiev-
ing a BCR-ABL1 transcript level 0.1% at 24 months using RQ-PCR. When CML patients failed
to achieve molecular response targets, they were either dose-escalated to 800 mg IM or switched
to NIL. Where intolerance or toxicity to IM was observed, patients were switched to NIL.
Patients enrolled in the TIDEL II trial were divided into two broad outcome groups: i) posi-
tive outcome (CML patients able to remain on IM and achieve target MMR at 24 months),
and ii) negative outcome (CML patients who did not achieve MMR at 24 months on IM
therapy). This study used inclusion and exclusion criteria; pregnant patients were excluded.
Patients found to be intolerant to IM, who switched to NIL and then achieved MMR at 24
months, were removed from analysis as they could not be assessed as MMR failures to IM
because they may have switched for non-biological reasons. Patients who achieved MMR on
IM constituted the positive group and patients who did not achieve MMR on IM were consid-
ered the negative group, which included i) patients who did not achieve MMR at 24 months
on IM; ii) patients, who had a suboptimal response to IM, switched to NIL and went on to
achieve MMR at 24 months since MMR was not achieved by administering IM; and iii)
patients who received IM followed by NIL and did not achieve MMR at 24 months.
Predictive Factors
We investigated the relation between MMR at 24 months and common predictive factors in
the medical literature as mentioned in the Related Work section. Table 2 shows the list of pre-
dictive factors including description, factor type, and median with range values. All clinical,
molecular, and predictive assays and peripheral blood factors were collected at the time of
diagnosis, as follows: i) clinical factors: age, gender, and spleen size measured in centimetres
below the costal margin; ii) molecular factors: BCR-ABL1 transcript level pre-therapy and
BCR-ABL1 transcript type; iii) predictive assays: OA and IC50IM; and iv) peripheral blood fac-
tors: white cell count (WCC), absolute neutrophil count (ANC), and eosinophil, basophil,
monocyte, lymphocyte, platelet, and blast counts.
Impute Missing Data
Missing values are a common problem in clinical trials. Medical data is usually collected for
specific purposes (diagnosis, monitoring or treatment) and medical research aims to achieve
desired outcomes by designing clinical studies to test and validate specific medical hypotheses.
Predicting Molecular Response in CML
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Medical data may involve incomplete data or missing values which may be caused by a lack of
information or discontinuation of study. There are three types of missing data: missing com-
pletely at random (MCAR), missing at random (MAR) and missing not at random (MNAR).
In the first type, MCAR, the absence of predictive factors value is unrelated to the outcome or
other predictive factors, while the second type, MAR, the missing predictive factor is not
related to missing values but may be related to observed data. The third type, MNAR, is con-
sidered non-ignorable missingness where the predictive factor missing value depends on the
factor itself [26]. We aimed to have high quality predictive performance on average for all
future cases using the population-based model, in contrast to the construction of patient-spe-
cific models, which are influenced by the particular predictive factor of the patient case at
hand. Our population-based model is commonly used to perform well on average in all future
cases. Therefore, we considered 10% as the cut-off for including a predictive factor in the anal-
ysis, since removing patient data has the undesired effect of reducing patient datasets, thus
affecting the performance of the learned predictive model [27]. Missing data were treated
using imputation [28] and not by removing patients who might carry information for predic-
tion from other molecular data available. In imputation techniques, missing values are re-
placed with values estimated from suitable statistical methods based on information available
in the dataset. For example, the imputation of missing values for blood counts were derived
Table 2. Predictive factor descriptions, factor type and median with range values.
Factors Description Type Median
(Range)
Age (years) Clinical factor recorded at the time of diagnosis Continuous 49 (17–81)
Gender Clinical factor recorded at the time of diagnosis Categorical
Spleen (cm) Clinical factor measured by observation at diagnosis Continuous 3.8 (0–30)
BCR-ABL1 Transcript Type Genetic factor identified by quantitative PCR analysis to BCR-ABL1. Transcript b2a2 or
b3a2 is distinguished only by the absence of 75 nucleotides. Both b2a2 and b3a2 occur in
patients with linked polymorphisms within exon 13 (b2) and intron 13 of the BCR gene.
Categorical
OA (ng/200,000 cells) The OCT-1 protein activity as a protein function can be measured by uptake in the presence
and absence of a specific OCT-1 inhibitor in mRNA.
Continuous 4.7 (0–16.32)





Real-time quantitative polymerase chain reaction (RQ-PCR) can measure the level of
BCR-ABL1 transcripts in the peripheral blood of the patient.
Continuous 107.14 (1.96–
969)
ANC (109 /L) Biological factor (neutrophil, granulocytes) that can be measured from peripheral blood Continuous 32.59 (0.5–
219.2)
Monocytes (109 /L) Biological factor in white blood cells that can be measured from peripheral blood Continuous 1.7 (0–13.02)
Lymphocytes (109 /L) Biological factor in white blood cells that can be measured from peripheral blood Continuous 3.37 (0–13.9)
Basophils (109 /L) Biological factor in white blood cells that can be measured from peripheral blood Continuous 2.16 (0–
38.89)
Eosinophils (109 /L) Biological factor in white blood cells that can be measured from peripheral blood Continuous 1.11 (0–
17.81)
WCC (109 /L) Biological factor and important cells in CML that can be measured from peripheral blood. Continuous 49.6 (1.1–
353.50)
Blasts (109 /L) Biological factor that can be measured from peripheral blood Continuous 1.27 (0–13.9)
Platelets (109 /L) Biological factor that can be measured from peripheral blood Continuous 485 (91–
1219)
Sokal Score[15] Risk score developed in 1984 Continuous 1 (0.45–8.08)
Hasford Score[16] Risk score developed in 1998 Continuous 801 (0–
2137.6)
EUTOS Score[17] Risk score developed in 2011 Continuous 46.94 (0–
228.5)
doi:10.1371/journal.pone.0168947.t002
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from known values of blood count range, and the effect of missing data on estimate of variance
was beyond the scope of this study. We used linear interpolation [29] values to impute contin-
uous and categorical data. We used the impute command in SPSS to replace missing values
with linear interpolation estimation values from the last valid value before the missing value
and the first valid value after the missing value. The corresponding correlation values for the
original dataset (with missing values) and completed dataset (without missing values) were cal-
culated to indicate whether imputation affected the dataset.
Reformatting Predictive Factors Using Domain Knowledge
We reformatted factor values of data stored as text, numerals, or mixed type using existing knowl-
edge, such as standard boundaries of blood counts, domain knowledge of clinical expertise, and
previous medical publications [13, 14, 30]. Although the selected machine learning techniques
have the capacity to handle continuous predictor values, reformatting the data by categorising
each factor in the TIDEL II dataset into subgroups assisted comprehensibility of the final predic-
tive model [31]. For example, we categorised the value of IC50IM equal to 0.5 μM as low IC50
IM
and reformatted the index number of the category. If the final model selected IC50IM as a relevant
predictive factor, we used these categories to distinguish the predictive group on test patients.
Machine Learning Methods
The main goal was to produce a useful predictive model that is understandable for all users.
Machine learning, such as SVM and neural networks, are difficult to interpret, while logistic
regression and naive Bayes allow easy interpretation of results. However, the main issue with
these algorithms are the strong assumptions of conditional independence between predictive
factors. They also assess the contribution of each predictive factor to classification, but not the
relations. The k-nearest neighbours[32] technique is another well-known machine leaning algo-
rithm, but it is sensitive to local structure of data. Classification and regression trees (CART)
[33] tend to be easily interpreted by clinicians. This method has the ability to learn relationships
between predictive factors and molecular response. The importance of a clear predictive model
stems from the need to trust the computation to predict response. In addition, clinicians need
to understand model recommendations to explain the reasons for their decision [31].
CART is a binary recursive partitioning process capable of processing continuous and cate-
gorical data as predictors or outcomes. The CART mechanism produces the optimal tree after
pruning based on a cost function to avoid overfitting in the maximal tree. The steps are pro-
vided below for the basic algorithm of a decision tree, previously having been described in [33]:
1. The top-down recursive and divide-and-conquer style is used to construct the tree.
2. The root node is located in the top-most node of the tree.
3. Each node denotes a test on a factor and each branch indicates an outcome of the test,
where the leaf nodes represent classes. For selected factors, the data are recursively parti-
tioned. Here, a splitting criterion called the Gini Impurity Measure is used to determine
the best split in each node.
4. For given node t, the Gini index calculates the relative frequency of class c at node t as in
(1):




The following scenarios demonstrate the possible indication of using the Gini index
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measure. In the worst scenario, patient outcomes in training data using the examined split value
of predictive factor are equally distributed between both classes at the node that maximises Gini
value to indicate the least interesting information. However, in the best scenario, the minimum
Gini value is the most interesting information for ascertaining when all patient outcomes in
training data belong to one class using the examined split value of predictive factor [34].
5. The following three conditions are used to stop splitting:
• For the given node, all the tested data belong to the same class.
• No factors remain for splitting.
• No tested data are left for splitting
The starting point for this paper was a predictive model developed from a training set of
patient cases. We used CART for re-expressing the decision tree as a clearly expressed set of
clinical prediction rules that in the (IF..Then form) to identify relation between predictive fac-
tors and patient outcomes. CART has the ability to learn complex and non-linear relationships
between factors and the response. The decision tree structure represented the extracted pro-
duction rules [35]. Classifying a patient using a decision tree is effected by following a path of
predictive factors through the tree to one of the leaves (patient response). This path from the
root of the tree to a leaf establishes conditions which must be satisfied by any patient classified
by that leaf. Thus, each leaf of a decision tree corresponds to a prediction rule. These rules are
easier and lead to simple and clearer decisions which are more interpretable by clinicians than
‘black box’ mathematical models, such as SVM. The decision is generated on the basis of expert
experience. The prediction rules were in the form, IF A is S1 AND B is S2. . . THEN Response
is X, where A and B are the predictive factors, S1 and S2 are the subcategories that belong to A
and B, and X is the class (achieving MMR or not achieving MMR).
Predictive Factor Selection
Prior to using the machine learning algorithm feature selection, algorithms were often used to
select a relevant subset of input features (in our problem, a subset of predictive factors to deliver
a highly predictive model) [36, 37]. This is also very important in the context of healthcare costs
where fewer input factors imply fewer diagnostic tests to obtain relevant predictive factors [38].
We also need to extract relations between the most related predictive factors and to understand
whether prediction rules exist. We divided the feature selection process into two main types:
i) Knowledge-driven method for feature selection, such as existing medical knowledge
regarding the predictive factor as an informative feature or clinical expert judgment on molec-
ular factors associated with predicting MMR, known as manual feature selection [39],
including
• Predictive assays: OA, IC50IM.
• Molecular predictive factors: OA, IC50IM, BCR-ABL1 transcript level pre-therapy,
BCR-ABL1 transcript type.
ii) Data-driven methods for feature selection, known as automatic feature selection. We
used the wrapper approach[40] where all subsets of features are evaluated using a given
machine learning approach. The models resulting from the wrapper with each machine learn-
ing algorithm i were i = 1,2,. . .2n, where n is the number of predictive factors. CART was run
on the training data repeatedly using those subsets where predictive factor selection was only
in the root node.
Predicting Molecular Response in CML
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Evaluation Measurements
Performance of predictive models was measured by using a coincidence matrix. The problem
was presented as a binary classification where the test outcome was positive (achieved MMR)
or negative (did not achieve MMR). Results were divided into four conditions: (a) CML
patients correctly identified as not achieving MMR (‘True negative’ (TN)); (b) patients achiev-
ing MMR wrongly identified as not achieving MMR (‘False negative’ (FN)); (c) patients cor-
rectly identified as achieving MMR (‘True positive’ (TP)); and (d) patients not achieving MMR
wrongly identified as achieving MMR (‘False positive’ (FP)). We reported ‘accuracy, sensitiv-





















All predictive models were trained to minimise misclassification rate between predicted
MMR and actual MMR. In our predictive model, data were imbalanced in the positive and
negative patient groups. Two measures, G-mean (geometric mean) and F-score (weighted har-
monic mean of sensitivity and PPV), have often been used to assess performance of a predic-
tive model trained on imbalanced data as in (7 and 8):





F   score ¼
2  Sensitivity  PPV
Sensitivityþ PPV
ð8Þ
It is important to measure the balance between sensitivity and specificity, which means the
model correctly predicted both response groups (achieving MMR or not achieving MMR). We
also reported PPV (probability that a patient achieving MMR was correctly predicted to
achieve MMR) because high PPV means that few patients will be unpredicted, which is crucial
when making decisions in diagnosis pre-therapy. The PPV was calculated from the study test
data population, in which the prevalence was 48%.
Nested Cross-Validation
In traditional cross-validation, 10% of data (1 fold) is used for testing and the remainder
for training (9 folds), with training and testing performance repeated 10 times. Standard devia-
tion of performance of the 10 predictive models was estimated, considering they were inde-
pendent. The confidence interval was obtained from the mean and standard deviation at 95%
Predicting Molecular Response in CML
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confidence level. The summary of test performances calculated on unseen folds was considered
as the final performance.
However, when data are scarce, an extra layer of cross-validation should be performed.
Since the test set cannot be touched (it is saved to evaluate the final models), new cross-valida-
tion was conducted on the training set. This technique is known as nested cross-validation
[41]. In this case, we separated the training set into training and validation (~75%). The
remaining 25% was used as the testing set. The model was trained on the training set; features
were selected on the validation set; and performance was evaluated on the test set. We treated
inner cross-validation as part of the model fitting procedure. To avoid overfitting, we com-
pared the difference between training performance and inner cross-validation of the selected
model. This procedure may be a good estimator of error for finding the best predictive model
and predictive factor selection [42]. Finally, we reported accuracy, sensitivity, specificity, PPV,
NPV, G-mean, and F-score of the testing set.
Model Selection
To compare resulting models we used the G-mean and F-score as criteria for model selection.
The wrapper approach often needs evolutionary calculations, leading to extensive processing
expense. Here, we ranked the resulting models based on G-mean and F-score measurements
and selected the highest values.
The last step in our method was to compare the models generated using different feature
selection techniques with current predictive assays and score systems (Table 1) based on G-
mean and F-score performance to make a final recommendation. The full procedures are
shown in (Fig 1), which is the schema of the CML predictive model.
External Validation Dataset
The external dataset was obtained from a tertiary care hospital, King Faisal Specialist Hospital
and Research Centre (KFSHRC), Riyadh, Saudi Arabia. There were 172 adult CML patients
who used frontline TKI[43]. Only patients using frontline IM with observed MMR at 24
months were selected. We performed pre-process steps to prepare the dataset for validation.
We applied inclusion and exclusion criteria, imputed missing values and reformatted predic-
tive factors using domain knowledge. We used evaluation measurements on predicted
response by the recommended model versus observed response: accuracy, sensitivity, specific-
ity, PPV, NPV, G-mean, and F score.
Ethics Statement
The data were analysed anonymously. All study participants provided written informed
consent prior to participation. The TIDEL II trial is registered at www.ANZCTR.org.au as
ACTRN12607000325404 and funded by Novartis Australia. The TIDEL II was carried out
with the approval of human research ethics committees (RAH Protocol No 070718c, and ethi-
cally approved by the National Statement on Ethical Conduct in Human Research (NHMRC),
2007 and in accordance with the Declaration of Helsinki. The KFSHRC data ethically ap-
proved by Clinical Research Committee (CRC) and Research Ethics Committee (REC), 2005,
Research Advisory Council (RAC) reference: ORA/1811/26, Proposal No 2051056.
Results
In this section, we first report the number of patients for various outcomes in the full TIDEL II
dataset. Then, we describe data preparation for analysis, including imputing missing values
Predicting Molecular Response in CML
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and reformatting predictive factors using domain knowledge. We reveal predictive perfor-
mance of the machine learning technique and the effect of feature selection methods on select-
ing the final model. We also present evaluation results on unseen data based on a comparison
Fig 1. The schema for the CML predictive model, building, evaluation, and final model selection. To build
the predictive model, we studied a clinical trial, preparing data for analysis by imputing missing values and
reformatting factors using comprehensive standard boundaries to create subcategories for each predictive factor
based on domain knowledge. For evaluation and final model selection, the nested design was used to split the
dataset into training, validation and testing sets. The model was trained on the training set, features were selected
on the validation set, and performance was evaluated on the test set. The final models were compared with
previous methods.
doi:10.1371/journal.pone.0168947.g001
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with previous methods. Finally, we demonstrate the strong predictive factors associated with
MMR at 24 months and extract the rules for prediction.
Insight into the Data
In the TIDEL II clinical trial, among the 210 patients and under the inclusion/exclusion criteria,
analysis included 173 (82.3%) CML patients. A positive outcome was observed in 102 (48.5%)
patients able to remain on IM and achieve the target of MMR at 24 months (positive outcome),
compared with 71 (33.8%) patients showing a negative outcome. The remaining 37 (34.7%)
patients were excluded from analysis due to pregnancy or intolerance to IM, who were switched
to NIL and then achieved MMR at 24 months. We split the TIDEL II cohort into training and
testing sets. The training set included 123 (58.5%) patients and was used for inner cross-valida-
tion; the remaining 50 (23.8%) patients (testing set) were utilised for comparison between
published predictive methods and our final models. The positive group was comprised of 76
training (74%) and 26 testing (26%) patients, while the negative group was compromised of 47
training (66%) and 24 testing (34%) patients. The 71 patients in negative group included i) 15
training and 4 testing of 19 (11%) patients who did not achieve MMR at 24 months on IM;
ii) 13 training and 6 testing of 19 (11%) patients who had suboptimal response to IM, were
switched to NIL and went on to achieve MMR at 24 months as MMR was not achieved by
administering IM; and iii) 19 training and 14 testing of 33 (19%) patients who received IM fol-
lowed by NIL and did not achieve MMR at 24 months. Additional details about the number of
patients in the study and inclusion and exclusion criteria are shown in Fig 2.
Imputation for Missing Values
Correlation coefficient results obtained with original data (with missing values) and complete
data (missing values imputed by linear interpolation) are presented in (Tables A-C in S1 Text).
We used the complete dataset for analysis. In TIDEL II, missing values were <10% as well as
the external validation dataset.
Reformat Predictive Factors Using Domain Knowledge
Knowledge was derived from standard boundaries of blood counts, clinical expertise, and pre-
vious medical publications [13, 14, 30]. The categories for each predictive factor used to trans-
form data into categorical data and number of patients are shown in Table 3.
Predictive Factor Selection and Prediction Results
The machine learning algorithm was trained for each feature selection method, once with all
features, once with molecular features, and once with all subsets using the wrapper approach.
In the wrapper approach, all subsets were trained to include different predictive factors. Here,
model selection criteria were accuracy, G-mean, and F-score, which resulted from inner cross-
validation performance on the training set. Predictive performance of feature selection meth-
ods with the machine learning technique on the training set is provided in Table 4. In the
table, training performance and inner cross-validation performance are also presented to show
fit of the models. Models A, B, and C have overfitting problems where training accuracy (A:
81%, B: 64%, C: 70%) is much larger than the cross validation mean of accuracy (A: 51%, B:
57%, C: 50%). However, the three models selected based on achieving high cross-validation
mean performances (accuracy, G-mean, F-score) achieved training accuracy (D: 78%, E: 77%,
F: 73%), compared with the cross-validation mean of accuracy (D: 76%, E: 75%, F: 76%); there-
fore, these were better models.
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Comparison of Final Models and Previous Methods
We measured performance on the testing set of single predictive assays commonly used to pre-
dict MMR (OA and IC50IM) and common prognostic risk scores (Sokal, Hasford, EUTOS)
(Table 5). OA achieved the highest accuracy (68%) compared with other previous methods
(IC50IM: 54%, Sokal: 58%, Hasford: 56%, EUTOS: 52%). However, Model D (accuracy: 72%)
outperformed OA (accuracy: 68%). Although, the Hasford score accurately predicted the posi-
tive group (those that achieved MMR at 24 months) with a sensitivity of 92%, and IC50IM
accurately predicted the negative group (those that did not achieve MMR at 24 months) with a
specificity of 75%, G-mean (IC50IM: 50%, Hasford: 39%) did not exceed that of OA (67%). The
three scores achieving high sensitivity (Sokal: 84%, Hasford: 92%, EUTOS: 84%) are therefore
good predictors of the positive group. The highest G-mean and F-score values among previous
methods were achieved by OA (G-mean: 67%, F-score: 69%). On the other hand, Models D, E,
and F had G-mean and F-score values that outperformed OA performance. In addition, our
models achieved PPV values better than previous methods. The PPV performances in our
Fig 2. TIDEL II patients in this study. Inclusion and exclusion criteria.
doi:10.1371/journal.pone.0168947.g002
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Table 3. The categories for each predictive factor used to transform data into categorical data and number of patients.
Factors Categories Patient in TIDEL II Patient in Saudi Population
No. of patient Patient % No. of patient Patient %
Age (years) Young30 21 12.21% 36 33.03%
Middle Age>30,60 104 60.47% 67 61.47%
Older>60 47 27.33% 6 05.50%
Gender Male 92 40.70% 45 41.28%
Female 118 59.30% 64 58.72%
Spleen (cm) Not palpable1 99 57.56% 52 47.71%
Small >1,10 44 25.58% 34 31.19%
Large >10 28 16.28% 23 21.10%
BCR-ABL1 Transcript Type b2a2 68 39.53% None None
b3a2 68 39.53% None None
Both 34 19.77% None None
e1a2 2 1.16% None None
OA (ng/200,000 cells) Low4 80 46.51% None None
Standard >4 87 50.58% None None
IC50IM (μM) Group 10.5 19 11.05% None None
Group 2 >0.50.7 31 18.02% None None
Group 3 >0.70.95 31 18.02% None None
Group 4 >0.95 79 45.93% None None
BCR-ABL1 level pretherapy (at diagnosis) Low20 8 4.65% None None
Moderate>20,100 96 55.81% None None
High>100 66 38.37% None None
ANC (109 /L) Low <1.8 3 1.74% None None
Normal1.8,7.5 35 20.35% None None
High >7.5, 50 97 56.40% None None
Very High >50 36 20.93% None None
Monocytes (109 /L) Low <0.2 16 9.30% 12 11.01%
Normal0.2,0.8 46 26.74% 23 21.10%
High >0.8 109 63.37% 74 67.89%
Lymphocytes (109 /L) Low <1 12 6.98% None None
Normal1,3.5 98 56.98% None None
High >3.5 61 35.47% None None
Basophils (109 /L) Normal0.1 28 16.28% 30 27.52%
High >0.1,1 76 44.19% 10 9.17%
Very High >1 67 38.95% 69 63.30%
Eosinophils (109 /L) Normal0.5 91 52.91% 28 25.69%
High >0.5 79 45.93% 81 74.31%
WCC (109 /L) Low <10 29 16.86% None None
Normal >10, <100 122 70.93% None None
High >100 20 11.63% None None
Blasts (109 /L) Normal >0,5 154 89.53% 99 90.83
High >5 13 7.56% 10 9.17%
Platelets (109 /L) Low20, <150 3 1.74% 8 7.34%
Normal >150,400 91 52.91% 53 48.62%
High >400 75 43.60% 48 44.04%
Sokal Score Low, intermediate1.2 132 79.51% 92 84.40%
High>1.2 34 20.48% 17 15.60%
(Continued)
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models (A: 73%, B: 84%, C: 80%, D: 88%, E: 84%, F: 96%) were higher than PPV in OA (67%).
These high PPV values indicated that our models could be trusted in making decisions at diag-
nosis pre-therapy.
Clinical Prediction Rules and Extraction of Relations between the
Predictive Factors and MMR Predictions
In this section, we demonstrate two findings: i) the selected predictive factors by CART algo-
rithm and ii) clinical prediction rules that clearly expressed the (IF..Then) conditional relation-
ship between the predictive factors and the MMR predictions.
Firstly, the CART uses only those factors that help separate response groups, while other
factors are not considered. All predictive factors were examined at each node to assess splitter
effectiveness. The decision tree generated by all features (Figure A in S1 File) had eight related
factors of 15 predictive factors after pruning the maximal tree: age, spleen size, platelets, eosin-
ophil, WCC, monocytes, IC50IM, and BCR-ABL1 transcript type.
Secondly, we extracted clinical prediction rules from selected models. The rule set is
attached in (S1 Table) and (Figures B and C in S1 File) represented the tree structure for
model E and model F respectively. To express the conditional relationship between predictive
factors and MMR predictions we presented examples from the molecular decision trees and
recommended model (model D). The first example is model B and model C that used molecu-
lar predictive factors, IC50IM divided patients into two groups. The groups with IC50IM >0.5
μM and IC50IM <0.95 μM were classified as the positive group, while for patients with IC50IM
<0.5 μM and IC50IM >0.95 μM, OA values can help identify MMR group. In model C, adding
BCR-ABL1 transcript level and transcript type identified further relations. In the group with
IC50IM >0.5 μM and IC50IM <0.95 μM, patients who had the b2a2 type may achieve MMR,
while the other type need more information about OA and BCR-ABL1 transcript level to iden-
tify MMR group. We also noticed that different MMR groups were identified based on the
same BCR-ABL1 transcript level. Thus, IC50IM, OA, and BCR-ABL1 transcript type affected
the role of BCR-ABL1 transcript level. We also demonstrate these relations in Fig 3.
The second example is model D. Although the CART with wrapper approach recom-
mended three models, model D showed best performance. In Fig 4, the conditional relation
between age, spleen size and MMR prediction is simply structured in the tree’s right branches.
For example, the first clinical prediction rule was IF spleen size belongs to the large size group
>10 cm AND age belongs to the young group30 or older group >60 THEN the patient may
achieve MMR. On the other hand, IF spleen size belongs to the large size group >10 cm AND
age belongs to the middle age group >30 and60 THEN the patient may not achieve MMR.
The accuracy of models measures how likely extracted rules are to correctly identify the MMR
group (Table 4, training performance).
Table 3. (Continued)
Factors Categories Patient in TIDEL II Patient in Saudi Population
No. of patient Patient % No. of patient Patient %
Hasford Score Low, Intermediate<1480 154 93.9% 101 92.66%
High1481 10 6% 8 7.34%
EUTOS Score Low<87 140 83.33% 92 84.40%
High87 28 16.67% 17 15.60%
Each predictive factor and the number of CML patients included in the study. Haematologist experts and previous publications identified the categories.
doi:10.1371/journal.pone.0168947.t003
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External Validation of the Final Model
The Model D was validated in the Saudi cohort. Inclusion and exclusion criteria were applied
to the dataset and the (Figure D in S1 File) shows the number of patients in the validation.
Table 3 shows the number of patients included in the validation for each predictive factor. We
included 109 patients who used frontline 400mg IM, while 63 (36%) patients were excluded
due to missing MMR values at 24 months (27 patients) or using frontline NIL or DAS (36
patients). There were 78 (72%) patients in the positive group who achieved MMR at 24 months
and 31 (28%) patients in the negative group as follows: i) 24 (77%) patients who did not
achieve MMR at 24 months on 400mg IM; ii) 2 (6%) patients who had a suboptimal response
to IM, switched to NIL and went on to achieve MMR at 24 months as MMR was not achieved
by administering IM; and iii) 5 (17%) patients who received IM followed by NIL or DAS and
did not achieve MMR at 24 months.
We compared performance of the recommended model (Model D) and common prognos-
tic risk scores (Sokal, Hasford and EUTOS) (see Table 6). Hasford score achieved the highest
accuracy (68%) compared with Sokal and our model (Sokal: 63%, Hasford: 67% and Model D:
50%). In addition, the EUTOS score achieved a slightly lesser G-mean and F-score perfor-
mance than our model D (the Saudi population’s G-mean: 44% vs. the EUTOS’s G-mean:
41%; and the Saudi population’s F-score: 29% vs. the EUTOS’s F-score: 25%); furthermore,
compared to the prognostic scores, our model D achieved the highest G-mean (44%) and F-
score (29%) overall. Although the common prognostic risk scores achieved better accuracies,
highest specificity (35%) was found in our model compared with common prognostic scores
(Sokal: 13%, Hasford: 6% and EUTOS: 19%) which confirmed that model D accurately pre-
dicted the negative group (those that will not achieve MMR at 24 months) with a specificity of
35%. Validation data from the Saudi population were performed similar to testing data from
TIDEL II as the three scores achieving high sensitivity (Sokal: 83%, Hasford: 92%, EUTOS:
Table 5. The comparison between previous methods and, our predictive models.
Testing Performance





OA[13] 0.68 0.73 0.62 0.67 0.68 0.67 0.69
IC50IM[14] 0.54 0.34 0.75 0.60 0.51 0.50 0.43
Sokal score[15] 0.58 0.84 0.29 0.56 0.63 0.49 0.67
Hasford Score
[16]
0.56 0.92 0.16 0.54 0.66 0.39 0.68
EUTOS Score
[17]
0.52 0.84 0.16 0.52 0.50 0.37 0.64
Our Model s Model A 0.60 0.59 0.61 0.73 0.45 0.60 0.65
Model B 0.62 0.59 0.69 0.84 0.37 0.64 0.69
Model C 0.58 0.56 0.61 0.80 0.33 0.59 0.65
Model D 0.72 0.67 0.81 0.88 0.54 0.74 0.76
Model E 0.66 0.62 0.73 0.84 0.45 0.67 0.71
Model F 0.64 0.59 0.87 0.96 0.29 0.72 0.73
The bolded value indicated the comparative values between our methods and the previous methods, Model
A = all predictive factors, Model B = OA and IC50IM, Model C = OA, IC50IM, BCR-ABL1 Transcript level
Pretherapy and BCR-ABL1 Transcript Type, Model D = CART algorithm with the highest accuracy value,
Model E = CART algorithm with the highest G-mean value, and Model F = CART algorithm with the highest
F-score value.
doi:10.1371/journal.pone.0168947.t005
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Fig 3. Tree structures for a) Model B and b) Model C. Relations between molecular predictive factors and MMR. The tree represents each predictive
factor in nodes. The node has two possible splits: it is connected to either the second predictive factor or the MMR group of patients in the positive or
Predicting Molecular Response in CML
PLOS ONE | DOI:10.1371/journal.pone.0168947 January 3, 2017 17 / 23
86%) are therefore good predictors of the positive group. Although PPV value in the EUTOS
score (73%) outperformed model D (68%), PPV above 60% indicated that our model could be
trusted in making decisions at diagnosis pre-therapy.
Discussion
We employed a widely used and practical machine learning technique to develop a predictive
model to support decisions related to treatment strategies for CML. Results indicate that the pre-
dictive model presented in this paper should be evaluated for potential clinical use. The early
prediction of MMR at 24 months could be effective at reducing failure rate of TKI. Although the
study analysed TIDEL II trial data, the methodology can be applied for different clinical trials.
Results of our study suggest that CML patients predicted not to achieve MMR at 24 months
owing to IM could then be treated with alternative therapies, including the second generation
TKIs NIL and DAS, or with more aggressive IM therapy, such as switching to NIL therapy and
close monitoring. By contrast, CML patients predicted to achieve MMR could safely be treated
with standard IM therapy with good clinical outcomes expected. The consequence of mistaken
classification and subsequent treatment with IM is most likely to be treatment failure and
higher risk of mortality.
OA with high G-mean accurately predicts both the positive group (a predictor for patients
who will achieve MMR at 24 months) and the negative group (a predictor for patients who will
not achieve MMR at 24 months). In addition, the high F-score for OA indicates it is a good
predictor for the positive group (sensitivity) and can be trusted in clinical practice. However,
negative group. This graphical structure illustrates the predictive rules. Predictive rules can be used on unseen data to predict the target. A predictive rule
of the form: IF (conditions) THEN (class) is equivalent to a path from the root node to leaf in the decision tree, (Yes: achieve MMR at 24 months) and (No:
did not achieve MMR at 24 months).
doi:10.1371/journal.pone.0168947.g003
Fig 4. Model D structure. The final model in the tree graph that achieved high accuracy performance.
doi:10.1371/journal.pone.0168947.g004
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the machine learning models often fitted the data better than previous methods (CART models
fit the data better than OA). An important aspect of the decision tree is being informed by his-
torical data and predicted unseen data so that data fits the model. However, in developing pre-
vious methods, researchers started with a model and checked whether data fit the proposed
model and predictions were obtained by assuming that data are normally distributed or line-
arly associated. In conventional statistical methods, as data is collected by researchers to exam-
ine specific medical hypotheses or answer specific clinical questions, the approach is about a
model fitting the data[44]. Thus, This predictive model was developed by addressing the chal-
lenge as a machine learning problem.
The results displayed in Tables 5 and 6 show that the small number of patients’ predictive
factors included in our study may lead to overfitting and may consequently affect their gener-
alization ability on unseen examples. We observed that the G-mean and F-score performances
were reduced from 74% and 76% in the internal validation of the testing data to 44% and 29%
in the external validation of the Saudi data. In the present study, it is particularly interesting to
notice the difference in performance between the prognostic scores and our model D that can
be beneficial for the molecular response prediction, owing to the reduced risk of misclassified
patients, who will not achieve MMR at 24 months. In addition, the difference in the prediction
accuracy obtained from the nested cross validation of the CART was small (Table 4), which
indicates that our models were not overfit. We pruned our trees based on a cost function in
order to avoid overfitting in the maximal tree. Also, we have constructed predictive models to
predict MMR positive and negative groups based on the pre-therapy predictive factors (i.e. the
clinical, molecular, and blood count factors) in order to learn patterns as clinical prediction
rules that are associated with a response to IM.
Indeed, the recommended decision tree model D was validated internally on TIDEL II clin-
ical trial data, and externally on the Saudi dataset. The highest G-mean, and F-score values in
the testing data (TIDEL II’s G-mean: 74% and F-score: 76%) and the external validation data
(Saudi population’s G-mean: 44% and F-score: 29%) compared with the prognostic scores’ G-
mean and F-score confirmed that our models are good predictors for positive and negative
groups, while the highest sensitivities in the testing data and the external validation data were
observed in prognostic scores in comparison with our model D, confirming that prognostic
scores were good predictors for a positive group. As the Hasford score achieved the highest
sensitivity in TIDEL II and the Saudi population (sensitivity: 92%), and the Sokal and EUTOS
scores achieved higher sensitivity than our model (TIDEL II: Sokal and EUTOS scores: 84%;
model D: 67%), similarly, the sensitivity of Sokal and EUTOS were higher than our model D
in the external validation data (Sokal score: 83%; EUTOS score: 86%; model D score: 55%).
Strengths and Limitations
The main strength of our study is the development of predictive models using domain knowl-
edge in construction of clinical prediction rules which can be applied for validation on
Table 6. The comparison between previous methods and our recommended model on Saudi
population.
Validation Performance
Accuracy Sensitivity Specificity PPV NPV Gmean F-score
Sokal score[15] 0.63 0.83 0.13 0.71 0.24 0.33 0.17
Hasford Score[16] 0.68 0.92 0.06 0.71 0.25 0.24 0.1
EUTOS Score[17] 0.67 0.86 0.19 0.73 0.35 0.41 0.25
Model D 0.50 0.55 0.35 0.68 0.24 0.44 0.29
doi:10.1371/journal.pone.0168947.t006
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different cohorts. We extracted hidden knowledge in the form of prediction rules. Another
strength is interpretability and high prediction performance of the decision tree model
developed using age, gender, spleen size, blasts, and monocytes. Also, the number of predic-
tive factors used in the model is another advantage in the context of healthcare costs as
fewer input factors imply fewer diagnostic tests to obtain relevant predictive factors [38].
From the wrapper approach, predictive factors determined to be relevant predictors of
MMR at 24 months were age, gender, spleen size, eosinophils, blasts, monocytes, OA,
BCR-ABL1 transcript level, and BCR-ABL1 transcript type. Indeed, considerable evidence
supports the significant impact of age[15, 16], gender[23], OA[13], spleen size[15–17],
blasts, and eosinophils [15, 16].
This study is the first to investigate relations between molecular predictive factors and
MMR. The levels of BCR-ABL1 transcript pre-therapy and BCR-ABL1 transcript type as
molecular tests play a role in investigating prediction of MMR achievement at 24 months.
We found that molecular factors could significantly increase model performances (Models
E and F), whereas Model D could be sufficient for prediction of MMR at 24 months. This
study does not ignore the significance of all predictive factors involved in the analysis
because different criteria (not maximising accuracy, G-mean, and F-score) may result in
different predictive factors.
We reported the performance of the three common prognostic scores in the Saudi popula-
tion (KFSHRC) and TIDEL II as part of the evaluation of model performance, but this appears
to be the first study to report these results, helping overcome the lack of research in the area of
comparing the performance of existing prognostic scores in both Saudi and Australian popula-
tions. Although the Australia group reported their Sokal score result from TIDELL II [25], it is
best to obtain the most reliable of the three prognostic performance scores and compare it
with the new development model. As our results demonstrate, the previous prognostic scores
are good predictors of the positive group, but our models are good predictors for both the pos-
itive and negative groups.
The tree structures were significantly influenced as the majority of patients had the same
outcome. A larger dataset may increase prediction accuracy. Additionally, varying expert opin-
ions in representing category boundaries of each predictive factor could dramatically change
performance of the models.
With the available options for CML treatment, development of a method to predict CML
patient response to treatment at diagnosis is critically important. We can conclude that this
predictive model assists managing CML treatment by predicting the likelihood that de novo
CML patients will achieve MMR at 24 months when treated with IM. The decision tree predic-
tion model presented here offers medical practitioners an additional tool to provide patients
with improved, individualised treatment plans. For future work, this method may also be
extended to other TKIs available for use as frontline CML therapy.
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